Unlock instant, AI-driven research and patent intelligence for your innovation.

MULTIPLEX ASSAY FOR DETERMINING beta-AMYLOID 42/40 RATIO IN HUMAN PLASMA SPECIMENS

An amyloid, ratio technology, applied in the preparation of test samples, measurement devices, biological tests, etc., can solve the problems of early AD detection and the uselessness of intervention

Pending Publication Date: 2022-02-18
QUEST DIAGNOSTICS INVESTMENTS INC
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these screening methods are useless for early AD detection and intervention because they focus on individuals exhibiting symptoms of advanced neurodegeneration

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • MULTIPLEX ASSAY FOR DETERMINING beta-AMYLOID 42/40 RATIO IN HUMAN PLASMA SPECIMENS
  • MULTIPLEX ASSAY FOR DETERMINING beta-AMYLOID 42/40 RATIO IN HUMAN PLASMA SPECIMENS
  • MULTIPLEX ASSAY FOR DETERMINING beta-AMYLOID 42/40 RATIO IN HUMAN PLASMA SPECIMENS

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0147] Patient plasma samples were manually diluted in dilution buffer to dissociate Aβ42 and Aβ40 from endogenous plasma proteins. Thaw each patient sample first, then vortex well. To achieve a 1:10 dilution, 30 μl of each patient sample was pipetted into a 1.5 ml snap-top tube containing 270 μl of Quanterix 4-Plex Diluent (Quanterix Corp., Mass. Lexington, State). The diluted patient samples were allowed to equilibrate at room temperature for at least 30 minutes but no more than 4 hours prior to further processing.

[0148] Amyloid β peptide controls consist of Aβ42 (e.g., β-amyloid (Aβ) [1-42] (human), Invitrogen #03-112) and Aβ40 (e.g., amyloid β protein 1-40, Sigma Aldrich #A1075 -1MG) stock solution preparation. From these stock solutions, "analogues" and high, medium, low concentration control. Each control solution was diluted 1:10 (60 μl pipetted into 540 μl of dilution buffer solution (eg, Quanterix 4-Plex diluent)).

[0149] A series of calibrators were prepar...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present technology relates to methods for diagnosing, monitoring the progression of, assessing the efficacy of treatment of, or assessing risk for development of a neurodegenerative disorder in a patient. These methods are based on determining the ratio of beta-amyloid 42 ("A beta42") to beta- amyloid 40 ("A beta40") in a body fluid sample collected from a patient who has or is suspected of having a neurodegenerative disorder, using an improved and highly sensitive multiplex protein assay that simultaneously detects A beta42 and A beta40.

Description

[0001] Cross References to Related Applications [0002] This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Application No. 62 / 846,565, filed May 10, 2019, which is hereby incorporated by reference in its entirety. technical field [0003] The present technology relates to methods for diagnosing a neurodegenerative disorder in a patient, monitoring the progression of a neurodegenerative disorder, evaluating the efficacy of a treatment for a neurodegenerative disorder, or assessing the risk of developing a neurodegenerative disorder. These methods are based on the determination of β-amyloid42 in body fluid samples collected from patients with or suspected of having a neurodegenerative disorder using an improved and highly sensitive multiplex protein assay for the simultaneous detection of Aβ42 and Aβ40 (“ Ratio of Aβ42") to β-amyloid 40 ("Aβ40"). Background technique [0004] The following description of the background of the present technology is p...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/68G01N33/53
CPCG01N33/6896G01N2333/4709G01N33/5306G01N2800/2821G01N1/34G01N33/543G01N2800/50G01N2800/52
Inventor K·R·莫诺B·G·桑索西
Owner QUEST DIAGNOSTICS INVESTMENTS INC